Key facts
- Mimicrete’s last known valuation is $4.6M (Jan 2023).
- It has raised $800K; the latest was Seed Round in Sep 2025.
- Notable investors include Innovate UK, SFC Capital, Village Capital, Morgan Stanley Inclusive Ventures Lab, Accelerate Cambridge — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Mimicrete
- ·The full record, as it builds
Funding rounds
No funding rounds for Mimicrete are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mimicrete
Developer of biomimetic self-healing concrete technologies designed to reduce the amount of concrete used and related carbon emissions, and lifetime structure monitoring and maintenance costs. The company heals concrete cracks as soon as they open up, mitigating further cracking and subsequent structural issues, which can lengthen concrete's lifetime and reduce the need for overengineering, repair or replacement, enabling the construction industry to improve the sustainability and durability of concrete structures.
- Sector
- Business Products and Services (B2B)
- HQ
- Cambridge, United Kingdom
- Founded
- 2021
- Employees
- 10
- Website
- mimicrete.com/
- Ownership
- Privately Held (backing)
Mimicrete doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mimicrete shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mimicrete in its N-PORT filings yet. We sweep new filings monthly.